Skip to main content
Log in

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome

A multicenter dose-response study

  • Intestinal Disorders, Inflammatory Bowel Disease, Irritable Bowel Syndrome, and Immunology
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The efficacy and safety of the peripheral kappa agonist fedotozine was evaluated in a double-blind, multicenter study involving 238 patients with the irritable bowel syndrome. After a two-week washout, patients were assigned to one of four groups to receive either placebo or fedotozine three times a day at doses of 3.5, 15, or 30 mg for six weeks. Patient assessment of mean symptom intensity indicated that the 30-mg dose of fedotozine was superior to placebo in relieving maximal daily abdominal pain (P=0.01), mean daily pain (P=0.007), and abdominal bloating (P=0.02). Changes in bowel function and defecation disorders could not be evaluated reliably. According to the investigators, the highest dose of fedotozine markedly reduced overall disease severity (P=0.003) and the pain component of the symptomatic profile (P=0.009). Clinical and laboratory safety was very good. Fedotozine 30 mg three times a day therefore appears to be effective and safe in the treatment of the abdominal pain and bloating associated with IBS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bommelaer G, Rouch M, Dapoigny M, Pais D, Loisy P, Gualino M, Tournut R. Epidémiologie des troubles fonctionnels intestinaux dans une population apparemment saine. Gastroenterol Clin Biol 10:7–12, 1986

    Google Scholar 

  2. Buéno L, Fioramonti J, Ruckebusch Y, Frexinos J, Colom P. Evaluation of colonic myoelectrical activity in health and functional disorders. Gut 21:480–485, 1980

    Google Scholar 

  3. Kellow JE, Phillips SF: Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 92:1885–1893, 1987

    Google Scholar 

  4. Lind CD: Motility disorders in the irritable bowel syndrome. Gastroenterol Clin North Am 20:279–295, 1991

    Google Scholar 

  5. Ritchie J: Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 14:125–132, 1973

    Google Scholar 

  6. Read NW: Irritable bowel syndrome (IBS)—definition and pathophysiology. Scand J Gastroenterol Suppl 130:7–13, 1987

    Google Scholar 

  7. Wingate DL: The irritable bowel syndrome. Gastroenterol Clin North Am 20:351–362, 1991

    Google Scholar 

  8. Diop L, Rivière P, Pascaud X, Junien JL: Peripheral kappa opioid receptors mediate the antinociceptive effect of fedotozine on the duodenal pain reflex in rat. Eur J Pharmacol 271:65–71, 1994

    Google Scholar 

  9. Rivière PJM, Pascaud X, Chevalier E, Le Gallou B, Junien JL: Fedotozine reverses ileus induced by surgery or peritonitis: Action at peripheral kappa opioid receptors. Gastroenterology 104:724–731, 1993

    Google Scholar 

  10. Rivière PJM, Pascaud X, Chevalier E, Junien JL: Fedotozine reversal of peritoneal irritation-induced ileus in rats: Possible peripheral action on sensory afferents. J Pharmacol Exp Ther 270:846–850, 1994

    Google Scholar 

  11. Gué M, Junien JL, Pascaud X, Bueno L: Antagonism of stress-induced motor alteration and plasma cortisol release by fedotozine (JO 1196) in dogs. J Gastrointest Motil 2:258–264, 1990

    Google Scholar 

  12. Gué M, Junien JL, Buéno L: The kappa agonist fedotozine modulates colonic distension-induced inhibition of gastric motility and emptying in dogs. Gastroenterology 107:1327–1334, 1994

    Google Scholar 

  13. Coffin B, Jian R, Lémann M, Fraitag B, Van Egroo LD, Franchisseur C, Rambauc JC: Fedotozine increases threshold of discomfort to gastric distension in healthy subjects. Gastroenterology 102:A437, 1992 (abstract)

    Google Scholar 

  14. Fraitag B, Homerin M, Hecketsweiler P: Double-blind doseresponse multicenter comparison of fedotozine and placebo in the treatment of nonulcer dyspepsia. Dig Dis Sci 39:1072–1077, 1994

    Google Scholar 

  15. Talley NJ, Piper DW: The association between nonulcer dyspepsia and other gastrointestinal disorders. Scand J Gastroenterol 20:896–900, 1985

    Google Scholar 

  16. Kirk RE: Experimental Design: Procedures for the Behavioral Sciences. 2nd ed. Pacific Grove, California, Brooks/Cole Publishing, 1982

    Google Scholar 

  17. Pattee PL, Thompson WG: Drug treatment of the irritable bowel syndrome. Drugs 44:200–206, 1992

    Google Scholar 

  18. Heaton KW, O'Donnell LJ, Braddon FE, Mountford RA, Hughes AO, Cripps PJ: Symptoms of irritable bowel syndrome in a British urban community: Consulters and nonconsulters. Gastroenterology 102:1962–1967, 1992

    Google Scholar 

  19. Manning AP, Thompson WG, Heaton KW, Lorris AF: Towards positive diagnosis of the irritable bowel. Br Med J 2:653–654, 1978

    Google Scholar 

  20. Talley NJ, Nyren O, Drossman DA, Heaton KW, Veldhuyzen van Zanten SJO, Koch MM, Ransohoff DF: The irritable bowel syndrome: Toward optimal design of controlled treatment trials. Gastroenterol Int 6:189–211, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Participating investigators: [France] Bataillon, Beaujard, Beranger, Boisson. Boboc, Bour, Bourry, Boyer, Cambon, Cassan, Chambon, Chery, Cosmidis, Dahlab, Dapoigny, Daudet, Debat, Delette. Delvaux, Desechalliers, Diez, Dumas, Faucher, Girard, Gislon, Hamelin, Hayek. Hecketsweiler, Joliot, Kornhauser, Lafon, Lamouliatte, Larche, Le Bihan, Legoux, Lirzin. Ljunggren, Marcheta, Marquier, Milon, Molinie, Monneris, Montoya, Morichau-Beauchant, Naudy, Pillegand, Raud Regeard, Renson, Richieri, Rouison, Rumeau, Salas, Staub, Vandermolen, Verbiese, Veyres, Wagner, Weber, Yousfi, Zani: [Tunisia] Ben Amar, Ben Kahlifa, Garoui, Hamza: [Belgium] Lamy, Lienard, Peeters.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dapoigny, M., Abitbol, J.L. & Fraitag, B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. Digest Dis Sci 40, 2244–2249 (1995). https://doi.org/10.1007/BF02209014

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02209014

Key Words

Navigation